register

News & Trends - Pharmaceuticals

The staggering potential for hep C elimination: A call for political will on World Hepatitis Day

Health Industry Hub | July 23, 2024 |

Despite making early headway towards the 2030 hepatitis C elimination goal, recent progress has stalled in Australia. Dr Joss O’Loan, General Practitioner and Co-Founder of the Kombi Clinic, alongside Dr Paul Slade, Country Medical Director at Gilead Sciences, underscored the urgency of this year’s World Hepatitis Day (28 July) theme, It’s time for action.

“The time for talk is over, the time for action is now if we are to achieve the elimination goals by 2030,” Dr O’Loan emphasised.

“What really inspired us to get on the road was this so called theory of a ‘hard to reach patient’,” Dr O’Loan explained, reflecting on the gaps in care and health inequalities that prompted the launch of the Kombi Clinic in 2017, an outreach model designed to bridge these divides.

“It’s not the patient that’s hard to reach. It’s the health service that’s hard to reach. It’s the doctor that’s hard to get to…”

This year, the Sixth National Hepatitis C Strategy 2023-2030 is set for public release after significant consultation over the past two years. The key question remains: will it drive bold action to support the 2030 elimination deadline?

“We’ve reached a stage where the prospect of elimination is real,” Dr Slade stated. “The challenge for us now is that we’re in a steady state.”

“The ability to eliminate a viral disease is pretty staggering. It’s not something that has been done many times in our history,” Dr O’Loan noted. “We just really need the political desire to achieve the 2030 goal.”

The 2024-25 Federal Budget committed to new investment of $23.7m over two years for hepatitis B and hepatitis C initiatives. While this government commitment is welcomed, Dr O’Loan stressed that continued funding is required to “embed” diagnostic testing and innovative models of care “in standard practice, without the little sugar hits in terms of budgets.”

Highlighting the importance of industry collaborations with diverse stakeholders to support the 2030 elimination deadline, Dr Slade said “We have to take a holistic view to be part of the solution…and help people make informed decisions.”

In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - Pharmaceuticals

Government inaction on mental illness faces overwhelming criticism ahead of federal election

Government inaction on mental illness faces overwhelming criticism ahead of federal election

Health Industry Hub | October 11, 2024 |

Pharma News: The Federal Government must strengthen its support for individuals with severe and complex mental illness to prevent future […]

More


News & Trends - Pharmaceuticals

New CVD model marks a critical step in the right direction

New CVD model marks a critical step in the right direction

Health Industry Hub | October 11, 2024 |

Pharma News: Cardiovascular disease (CVD) affects four million Australians and claims one life every 12 minutes. A recent heart screening […]

More


News & Trends - Pharmaceuticals

Alzheimer’s disease set to cost $17 billion: Lilly urges government to keep pace with innovation

Alzheimer’s disease set to cost $17 billion: Lilly urges government to keep pace with innovation

Health Industry Hub | October 11, 2024 |

Pharma News: A newly commissioned report by Lilly, unveiled at Parliament House, has shed light on the health, societal, and […]

More


Leadership & Management

J&J MedTech appoints new ANZ leader

J&J MedTech appoints new ANZ leader

Health Industry Hub | October 10, 2024 |

Leadership & Management: Johnson & Johnson has been appointed a new Managing Director for its medtech business in Australia and […]

More


This content is copyright protected. Please subscribe to gain access.